Dejgaard TF, von Scholten BJ, Christiansen E, et al. - The effectiveness and glycemic safety of liraglutide did not differ between subgroups in ADJUNCT ONE and ADJUNCT TWO, leaving residual beta-cell function as the only recognized variable influencing the action of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 1 diabetes (T1D). Such findings support a place for GLP-1 RAs as adjuncts to insulin in T1D and call for more research.

• ADJUNCT ONE and ADJUNCT TWO were randomized controlled phase 3 trials in 1,398 and 835 T1D patients treated with liraglutide (1.8, 1.2, or 0.6 mg) or placebo (adjuncts to insulin), respectively.

• At week 26, the decreases in HbA1c, body weight, and daily insulin dose did not vary significantly by baseline HbA1c or BMI in both trials.

• The risk of clinically significant hypoglycemia or hyperglycemia with ketosis was not significantly different based on baseline HbA1c, BMI, or insulin regimen.

• Such hazards did not differ across treatment groups at week 26 in ADJUNCT ONE.

• Placebo-adjusted reductions in HbA1c, body weight, and insulin dose were considerable, larger than at week 52, and comparable to those seen in ADJUNCT TWO.